Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

Links shared publicly online about this topic.

  • 1,719
    total visits

Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

medicalnewstoday.com —

Pfizer oncology announced today that it will initiate a global, phase 3 clinical trial of its investigational oral c-met and alk inhibitor, pf-02341066, versus standard of care chemotherapy in pat

View full resource at medicalnewstoday.com

Tags: Lung Cancer, Non-Small Cell Lung Cancer, Lung, Phase 3 Clinical Trial, Clinical Trial, Genes, Pfizer, Oncology

  • Share

Most Recently Shared on September 27, 2009 at 11:38 am By:

mnt_clinical MNT Clinical Trials

Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Spe.. http://bit.ly/htlRM

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cancer News MNT Cancer News

Advertisement